




Rec'd PCT/PTO 14 FEB 2005
PCT/EP 03/09211



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ



I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely affects the company to certain additional company law rules:

Signed

P. Mahoney

Dated 25 July 2003

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY



22AUG02 E742773-1 D01030
P01/7700 0.00-0219501.4

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

SCH/HG/P33099

2. Patent number

0219501.4

21 AUG 2002

(The Patent Office will fill in his part)

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Glaxo Group Limited
Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex UB6 0NN, Great Britain

Patents ADP number (if you know it)

473587003

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

Compounds

5. Name of your agent (if you have one)

Corporate Intellectual Property

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

GlaxoSmithKline
Corporate Intellectual Property (CN9 25.1)
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

Patents ADP number (if you know it)

7960982003

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	--	-------------------------------------

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	-------------------------------------

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer yes if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is named as an applicant, or
 - c) any named applicant is a corporate body
- See note (d)

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form
Description
Claim(s)
Abstract
Drawings

38
2

CF

10. If you are also filing any of the following,
state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right
to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination
and search (*Patents Form 9/77*)

Request for substantive examination
(*Patents Form 10/77*)

Any other documents
(please specify)

11.

We request the grant of a patent on the basis of this
application

Signature

S C Hockley

Date 20-Aug-02

12. Name and daytime telephone number of
person to contact in the United Kingdom

S C Hockley 01279 644355

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- For details of the fee and ways to pay please contact the Patent Office.*

Compounds

The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

Cannabinoids are a specific class of psychoactive compounds present in Indian cannabis (*Cannabis sativa*), including about sixty different molecules, the most representative being cannabinal, cannabidiol and several isomers of tetrahydrocannabinol. Knowledge of the therapeutic activity of cannabis dates back to the ancient dynasties of China, where, 5,000 years ago, cannabis was used for the treatment of asthma, migraine and some gynaecological disorders. These uses later became so established that, around 1850, cannabis extracts were included in the US Pharmacopoeia and remained there until 1947.

Cannabinoids are known to cause different effects on various systems and/or organs, the most important being on the central nervous system and on the cardiovascular system. These effects include alterations in memory and cognition, euphoria, and sedation. Cannabinoids also increase heart rate and vary systemic arterial pressure. Peripheral effects related to bronchial constriction, immunomodulation, and inflammation have also been observed. The capability of cannabinoids to reduce intraocular pressure and to affect respiratory and endocrine systems is also well documented. See e.g. L.E. Hollister, Health Aspects of Cannabis, Pharmacological Reviews, Vol. 38, pp. 1-20, (1986). More recently, it was found that cannabinoids suppress the cellular and humoral immune responses and exhibit antiinflammatory properties. Wirth et al., Antiinflammatory Properties of Cannabichrome, Life Science, Vol. 26, pp. 1991-1995, (1980).

In spite of the foregoing benefits, the therapeutic use of cannabis is controversial, both due to its relevant psychoactive effects (causing dependence and addiction), and due to manifold side effects that have not yet been completely clarified. Although work in this field has been ongoing since the 1940's, evidence indicating that the peripheral effects of cannabinoids are directly mediated, and not secondary to a CNS effect, has been limited by the lack of receptor characterization, the lack of information concerning an endogenous cannabinoid ligand and, until recently, the lack of receptor subtype selective compounds.

The first cannabinoid receptor was found to be mainly located in the brain, in neural cell lines, and, only to a lesser extent, at the peripheral level. In view of its location, it was called the central receptor ("CB1"). See Matsuda et al., "Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA," Nature, Vol. 346, pp. 561-564 (1990). The second cannabinoid receptor ("CB2") was identified in the spleen, and was assumed to modulate the non psychoactive effects of the cannabinoids. See Munro et al., "Molecular Characterization of a Peripheral Receptor for Cannabinoids," Nature, Vol. 365, pp. 61-65 (1993).

Recently, some compounds have been prepared which are capable of acting as agonists on both the cannabinoid receptors. For example, use of derivatives of dihydroxypyrrole-(1,2,3-d,e)-1,4-benzoxazine in the treatment of glaucoma and the use of derivatives of 1,5-diphenyl-pyrazole as immunomodulators or psychotropic agents in the treatment of various neuropathologies, migraine, epilepsy, glaucoma, etc are known. See U.S. Patent No. 5,112,820

and EP 576357, respectively. However, because these compounds are active on both the CB1 and CB2 receptor, they can lead to serious psychoactive effects.

The foregoing indications and the preferential localization of the CB2 receptor in the immune system confirms a specific role of CB2 in modulating the immune and antiinflammatory response to stimuli of different sources.

The total size of the patient population suffering from pain is vast (almost 300 million), dominated by those suffering from back pain, osteo-arthritic pain and post-operative pain. Neuropathic pain (associated with neuronal lesions such as those induced by diabetes, HIV, herpes infection, or stroke) occurs with lower, but still substantial prevalence, as does cancer pain.

The pathogenic mechanisms that give rise to pain symptoms can be grouped into two main categories:

- those that are components of inflammatory tissue responses (Inflammatory Pain);
- those that result from a neuronal lesion of some form (Neuropathic Pain).

Chronic inflammatory pain consists predominantly of osteoarthritis, chronic low back pain and rheumatoid arthritis. The pain results from acute and on-going injury and/or inflammation. There may be both spontaneous and provoked pain.

There is an underlying pathological hypersensitivity as a result of physiological hyperexcitability and the release of inflammatory mediators which further potentiate this hyperexcitability. CB2 receptors are expressed on inflammatory cells (T cells, B cells, macrophages, mast cells) and mediate immune suppression through inhibition of cellular interaction/ inflammatory mediator release. CB2 receptors may also be expressed on sensory nerve terminals and therefore directly inhibit hyperalgesia.


The role of CB2 in immunomodulation, inflammation, osteoporosis, cardiovascular, renal and other disease conditions is now being examined. In light of the fact that cannabinoids act on receptors capable of modulating different functional effects, and in view of the low homology between CB2 and CB1, the importance of developing a class of drugs selective for the specific receptor sub-type is evident. The natural or synthetic cannabinoids currently available do not fulfil this function because they are active on both receptors.

Based on the foregoing, there is a need for compounds which are capable of selectively modulating the receptor for cannabinoids and, therefore, the pathologies associated with such receptors. Thus, CB2 modulators offer a unique approach toward the pharmacotherapy of immune disorders, inflammation, osteoporosis, renal ischemia and other pathophysiological conditions.

The present invention provides novel pyrimidine derivatives of formula (I) and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions containing these compounds or derivatives, and their use as CB2 receptor modulators, which are useful in the treatment of a variety of disorders.

The present invention further comprises a method for treating disease mediated by CB2 receptors in an animal, including humans, which comprises administering to an animal in need thereof an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

The invention provides compounds of formula (I):



wherein:

10 Y is phenyl, optionally substituted with one, two or three substituents;

R¹ is selected from: hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl;


R² is (CH₂)_mR³ where m is 0 or 1;

or R¹ and R² together with N to which they are attached form an optionally substituted 5- or 6- membered non-aromatic heterocyclyl ring;

15 R³ is an optionally substituted 4- to 8- membered non-aromatic heterocyclyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted straight or branched C₁₋₁₀ alkyl or R⁵;

R⁴ is selected from: hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl, COCH₃, or SO₂Me;

20 R⁵ is



wherein p is 0, 1 or 2;

R⁶ is methyl, chloro or CH_xF_n wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to 3;

25 R⁷ is OH, C₁₋₆alkoxy, NR^{8a}R^{8b}, NHCOR⁹, NHSO₂R⁹, SO_qR⁹;

R^{8a} is H or C₁₋₆alkyl;

R^{8b} is H or C₁₋₆alkyl;

R⁹ is C₁₋₆alkyl;

q is 0, 1 or 2;

30 and pharmaceutically acceptable derivatives thereof.

Preferably Y is a substituted phenyl. More preferably at least one substituent is in the 3 position.

When Y is substituted, the substituent or substituents are preferably selected from: C₁₋₆ alkyl, halosubstituted C₁₋₆ alkyl, C₁₋₆ alkoxy, a hydroxy group, a cyano group, halo, a C₁₋₆alkyl sulfonyl group, CONH₂, NHCOCH₃, or COOH. Preferably Y is substituted by halo, cyano or methoxy, preferably in the 3 position.

Preferably R¹ is hydrogen.

Preferably R⁴ is hydrogen.

40 When R¹ and R² together with N to which they are attached form a 5- or 6- membered non-aromatic heterocyclyl ring which is substituted, or when R³ is substituted, the substituent or

substituents are preferably selected from: C₁₋₆ alkyl, C₁₋₆ alkoxy, a hydroxy group, a cyano group, halo or a sulfonyl group.

Preferably R⁶ is CH_xFn, more preferably CF₃.

Preferably R⁷ is OH.

5 Preferably when R³ is an optionally substituted C₃₋₈cycloalkyl group or an optionally substituted 4- to 8- membered nonaromatic heterocyclyl, m is 1.

Preferably, R³ is an optionally substituted C₃₋₆cycloalkyl group or an optionally substituted 4- or 6- membered nonaromatic heterocyclyl.

10 Preferably the compounds are selective for CB2 over CB1. More preferably the compounds are 100 fold selective.

The invention is described using the following definitions unless otherwise indicated.

15 The term "pharmaceutically acceptable derivative" means any pharmaceutically acceptable salt, ester, salt of such ester or solvate of the compounds of formula (I), or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.

It will be appreciated by those skilled in the art that compounds of formula (I) may be modified to provide pharmaceutically acceptable derivatives thereof at any of the functional groups in the compounds, and that the compounds of formula (I) may be derivatised at more than one position.

20 It will be appreciated that, for pharmaceutical use, the salts referred to above will be physiologically acceptable salts, but other salts may find use, for example in the preparation of compounds of formula (I) and the physiological acceptable salts thereof. Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse, J. Pharm. Sci., 1977, 66, 1-19. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-
 25 toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as
 30 arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropyl amine, tromethamine, and the like. When the compound of the present invention is basic, salts
 35 may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.

40 Preferred examples of pharmaceutically acceptable salts include the ammonium, calcium, magnesium, potassium, and sodium salts, and those formed from maleic, fumaric, benzoic, ascorbic, pamoic, succinic, hydrochloric, sulfuric, bismethylenesalicylic, methanesulfonic, ethanedisulfonic,

propionic, tartaric, salicylic, citric, gluconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, cyclohexylsulfamic, phosphoric and nitric acids.

The terms 'halogen or halo' are used to represent fluorine, chlorine, bromine or iodine.

5 The term 'alkyl' as a group or part of a group means a straight or branched chain alkyl group or combinations thereof, for example a methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, pentyl, hexyl, 1,1-dimethylethyl, or combinations thereof.

10 The term 'alkoxy' as a group or as part of a group means a straight, branched or cyclic chain alkyl group having an oxygen atom attached to the chain, for example a methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy group, pentoxy, hexyloxy group, cyclopentoxy or cyclohexyloxy group.

The term 'cycloalkyl' means a closed 4- to 8- membered non-aromatic ring, for example cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, or cyclooctyl.

15 When R^1 and R^2 taken together with the N to which they are attached form an optionally substituted heterocyclyl ring, the ring may optionally contain 1, 2, 3 or 4 further hetero atoms. Preferably the further hetero atoms are selected from oxygen, nitrogen or sulphur. Examples of 5- membered heterocyclyl rings include pyrrolidinyl, Examples of 6-membered heterocyclyl rings are morpholinyl, piperizinyl or piperidinyl.

20 When R^3 is an optionally substituted non-aromatic heterocyclyl group, the ring may contain 1, 2, 3, or 4 hetero atoms. Preferably the hetero atoms are selected from oxygen, nitrogen or sulphur. Examples of 5- membered heterocyclyl groups in this instance include dioxalanyl, pyrrolidinyl or tetrahydrofuranyl or tetrahydrothiophenyl. Examples of 6-membered heterocyclyl groups are morpholinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, thiomorpholinyl or thiomorpholinyl-s,s-dioxide.

Preferred compounds of the present invention can be selected from:

25 [2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-piperidin-1-ylmethanone;
2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid
cyclopentylmethanamide;
[2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone;
2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-
30 (cyclohexylmethyl)amide;
2-Phenylamino-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide;
2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone;
[2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone;
[2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone;
35 [2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone;
[2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone;
[2-(3-Bromophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone;
[2-(3-Bromophenylamino)-4-trifluoromethylpyrimidin-5-yl]-piperidin-4-ylmethanone;
[2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone;
40 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidin-5-carboxylic acid N-cyclopentylamide;
2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-
(cyclohexylmethyl)amide;

- 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide;
 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide;
- 5 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide;
 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide;
 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-
- 10 (cyclohexylmethyl)amide;
 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide;
 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydro-pyran-4-ylmethyl)amide;
- 15 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidin-5-carboxylic acid N-cyclobutylamide;
 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide;
 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide;
- 20 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide;
 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide;
 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-
- 25 4-ylmethyl)amide;
 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide;
 2-(3-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide;
- 30 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide;
 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide;
 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-
- 35 (cyclopentylmethyl)amide;
 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide;
 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide;
- 40 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide;
 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide;

2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide;

2-(3-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide;

5 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide;

2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide;

2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide;

2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide;

2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide;

10 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide;


2-(3-methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide;

2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclobutylmethyl)amide;

and pharmaceutically acceptable derivatives thereof.

15

Compounds of formula (I) can be prepared as set forth in the following scheme:



wherein L is a leaving group, for example halo, P is a protecting group for example methyl, ethyl or benzyl, and R¹, R², R⁴, R⁶ and Y are as defined for compounds of formula (I).

25 It is to be understood that the present invention encompasses all isomers of compounds of formula (I) and their pharmaceutically acceptable derivatives, including all geometric, tautomeric and optical forms, and mixtures thereof (e.g. racemic mixtures). Where additional chiral centres

are present in compounds of formula (I), the present invention includes within its scope all possible diastereoisomers, including mixtures thereof. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

5 The compounds of the invention bind selectively to the CB2 receptor, and are therefore useful in treating CB2 receptor mediated diseases.

10 In view of their ability to bind to the CB2 receptor, the compounds of the invention may be useful in the treatment of the disorders that follow. Thus, the compounds of formula (I) may be useful as analgesics. For example they may be useful in the treatment of chronic articular pain (e.g. rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis) including the property of disease modification and joint structure preservation; musculoskeletal pain; lower back and neck pain; sprains and strains; neuropathic pain; sympathetically maintained pain; myositis; pain associated with cancer and fibromyalgia; pain associated with migraine; pain associated with influenza or other viral infections, such as the common cold; rheumatic fever; pain associated with functional bowel disorders such as non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome; pain associated with myocardial ischemia; post operative pain; headache; toothache; and dysmenorrhea.

15 The compounds of the invention may be particularly useful in the treatment of neuropathic pain. Neuropathic pain syndromes can develop following neuronal injury and the resulting pain may persist for months or years, even after the original injury has healed. Neuronal injury may occur in the peripheral nerves, dorsal roots, spinal cord or certain regions in the brain. Neuropathic pain syndromes are traditionally classified according to the disease or event that precipitated them. Neuropathic pain syndromes include: diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; post-herpetic neuralgia; trigeminal neuralgia; and pain resulting from physical trauma, amputation, cancer, toxins or chronic inflammatory conditions. These conditions are difficult to treat and although several drugs are known to have limited efficacy, complete pain control is rarely achieved. The symptoms of neuropathic pain are incredibly heterogeneous and are often described as spontaneous shooting and lancinating pain, or ongoing, burning pain. In addition, there is pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static or thermal allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).

35 The compounds of formula (I) may also be useful in the treatment of fever.

40 The compounds of formula (I) may also be useful in the treatment of inflammation, for example in the treatment of skin conditions (e.g. sunburn, burns, eczema, dermatitis, psoriasis); ophthalmic diseases such as glaucoma, retinitis, retinopathies, uveitis and of acute injury to the eye tissue (e.g. conjunctivitis); lung disorders (e.g. asthma, bronchitis, emphysema, allergic rhinitis, respiratory distress syndrome, pigeon fancier's disease, farmer's lung, chronic obstructive pulmonary disease, (COPD); gastrointestinal tract disorders (e.g. aphthous ulcer, Crohn's disease, atopic gastritis, gastritis varialoforme, ulcerative colitis, coeliac disease, regional ileitis, irritable

bowel syndrome, inflammatory bowel disease, gastrointestinal reflux disease); organ transplantation; other conditions with an inflammatory component such as vascular disease, migraine, periarteritis nodosa, thyroiditis, aplastic anaemia, Hodgkin's disease, scleroderma, myaesthesia gravis, multiple sclerosis, sarcoidosis, nephrotic syndrome, Bechet's syndrome, polymyositis, gingivitis, myocardial ischemia, pyrexia, systemic lupus erythematosus, tendinitis, bursitis, and Sjogren's syndrome.

The compounds of formula (I) are also useful in the treatment of immunological diseases such as autoimmune diseases, immunological deficiency diseases or organ transplantation. The compounds of formula (I) are also effective in increasing the latency of HIV infection.

The compounds of formula (I) are also useful in the treatment of diseases of abnormal platelet function (e.g. occlusive vascular diseases).

The compounds of formula (I) are also useful for the preparation of a drug with diuretic action.

The compounds of formula (I) are also useful in the treatment of impotence or erectile dysfunction.

The compounds of formula (I) are also useful for attenuating the hemodynamic side effects of non-steroidal anti-inflammatory drugs (NSAID's) and cyclooxygenase-2 (COX-2) inhibitors.

The compounds of formula (I) are also useful in the treatment of neurodegenerative diseases and neurodegeneration such as dementia, particularly degenerative dementia (including senile dementia, Alzheimer's disease, Pick's disease, Huntingdon's chorea, Parkinson's disease and Creutzfeldt-Jakob disease, motor neuron disease); vascular dementia (including multi-infarct dementia); as well as dementia associated with intracranial space occupying lesions; trauma; infections and related conditions (including HIV infection); metabolism; toxins; anoxia and vitamin deficiency; and mild cognitive impairment associated with ageing, particularly Age Associated Memory Impairment.

The compounds of formula (I) are also useful in neuroprotection and in the treatment of neurodegeneration following stroke, cardiac arrest, pulmonary bypass, traumatic brain injury, spinal cord injury or the like.

The compounds of formula (I) are also useful in the treatment of tinnitus.

The compounds of formula (I) are also useful in preventing or reducing dependence on, or preventing or reducing tolerance or reverse tolerance to, a dependence - inducing agent. Examples of dependence inducing agents include opioids (e.g. morphine), CNS depressants (e.g. ethanol), psychostimulants (e.g. cocaine) and nicotine.

The compounds of formula (I) are also useful in the treatment of kidney dysfunction (nephritis, particularly mesangial proliferative glomerulonephritis, nephritic syndrome), liver dysfunction (hepatitis, cirrhosis), gastrointestinal dysfunction (diarrhoea) and colon cancer.

It is to be understood that references to treatment includes both treatment of established symptoms and prophylactic treatment unless explicitly stated otherwise.

According to a further aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in human or veterinary medicine.

According to another aspect of the invention, we provide a compound of formula (I) or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the activity of cannabinoid 2 receptors.

According to a further aspect of the invention, we provide a method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

According to a further aspect of the invention we provide a method of treating a human or animal subject suffering from an immune disorder, an inflammatory disorder, pain, osteoporosis or a renal disorder which method comprises administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

According to another aspect of the invention is provided the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the manufacture of a therapeutic agent for the treatment or prevention of a condition such as a pain, inflammatory disorder, immunedisorder, osteoporosis or renal disorder.

In order to use a compound of formula (I) or a pharmaceutically acceptable derivative thereof for the treatment of humans and other mammals it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. Therefore in another aspect of the invention is provided a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof adapted for use in human or veterinary medicine.

As used herein, "modulator" means both antagonist, agonist and inverse agonist. Preferably the present modulators are agonists.

Compounds of formula (I) and their pharmaceutically acceptable derivatives may be administered in a standard manner for the treatment of the indicated diseases, for example orally, parenterally, sub-lingually, dermally, intranasally, transdermally, rectally, via inhalation or via buccal administration.

Compositions of formula (I) and their pharmaceutically acceptable derivatives which are active when given orally can be formulated as syrups, tablets, capsules and lozenges. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, peanut oil, olive oil, glycerine or water with a flavouring or colouring agent. Where the composition is in the form of a tablet, any pharmaceutical carrier routinely used for preparing solid formulations may be used. Examples of such carriers include magnesium stearate, terra alba, talc, gelatin, acacia, stearic acid, starch, lactose and sucrose.

Where the composition is in the form of a capsule, any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule any pharmaceutical carrier routinely used for preparing dispersions or suspensions may be considered, for example aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.

Typical parenteral compositions consist of a solution or suspension of a compound or derivative in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone, lecithin, arachis oil or sesame oil.

Typical compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered as a dry powder or in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane.

5 A typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable derivative thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gélatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogs.

10 Typical dermal and transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.

Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose.

15 Each dosage unit for oral administration contains suitably from 0.1 mg to 500 mg/Kg, and preferably from 1 mg to 100 mg/Kg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 100 mg/Kg, of a compound of formula(I) or a pharmaceutically acceptable derivative thereof calculated as the free acid. Each dosage unit for intranasal administration contains suitably 1-400 mg and preferably 10 to 200 mg per person. A topical formulation contains suitably 0.01 to 5.0% of a compound of formula (I).

20 The daily dosage regimen for oral administration is suitably about 0.01 mg/Kg to 40 mg/Kg, of a compound of formula(I) or a pharmaceutically acceptable derivative thereof calculated as the free acid. The daily dosage regimen for parenteral administration is suitably about 0.001 mg/Kg to 40 mg/Kg, of a compound of formula (I) or a pharmaceutically acceptable derivative thereof calculated as the free acid. The daily dosage regimen for intranasal administration and oral inhalation is suitably about 10 to about 500 mg/person. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity.

25 The CB₂ receptor compounds for use in the instant invention may be used in combination with other therapeutic agents, for example COX-2 inhibitors, such as celecoxib, deracoxib, rofecoxib, valdecoxib, parecoxib or COX-189; 5-lipoxygenase inhibitors; NSAID's, such as aspirin, diclofenac, indomethacin, nabumetone or ibuprofen; leukotriene receptor antagonists; DMARD's such as methotrexate; adenosine A1 receptor agonists; sodium channel blockers, such as lamotrigine; NMDA receptor modulators, such as glycine receptor antagonists; gabapentin and related compounds; tricyclic antidepressants such as amitriptyline; neurone stabilising antiepileptic drugs; mono-aminergic uptake inhibitors such as venlafaxine; opioid analgesics; local anaesthetics; 5HT₁ agonists, such as triptans, for example sumatriptan, naratriptan, zolmitriptan, eletriptan, frovatriptan, almotriptan or rizatriptan; EP₁ receptor ligands, EP₄ receptor ligands; EP₂ receptor ligands; EP₃ receptor ligands; EP₄ antagonists; EP₂ antagonists and EP₃ antagonists; bradykinin receptor ligands and vanilloid receptor ligand. When the compounds are used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.

40 Additional COX-2 inhibitors are disclosed in US Patent Nos. 5,474,995 US5,633,272; US5,466,823, US6,310,099 and US6,291,523; and in WO 96/25405, WO 97/38986, WO 98/03484, WO 97/14691, WO99/12930, WO00/26216, WO00/52008, WO00/38311, WO01/58881 and WO02/18374.

The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent or agents.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention. The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When a compound of formula (I) or a pharmaceutically acceptable derivative thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

Determination of cannabinoid CB1 Receptor Agonist Activity

The cannabinoid CB1 receptor agonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.

Experimental Method

Yeast (*Saccharomyces cerevisiae*) cells expressing the human cannabinoid CB1 receptor were generated by integration of an expression cassette into the *ura3* chromosomal locus of yeast strain MMY23. This cassette consisted of DNA sequence encoding the human CB1 receptor flanked by the yeast GPD promoter to the 5' end of CB1 and a yeast transcriptional terminator sequence to the 3' end of CB1. MMY23 expresses a yeast/mammalian chimeric G-protein alpha subunit in which the C-terminal 5 amino acids of Gpa1 are replaced with the C-terminal 5 amino acids of human Gai3 (as described in Brown *et al.* (2000), *Yeast* 16:11-22). Cells were grown at 30°C in liquid Synthetic Complete (SC) yeast media (Guthrie and Fink (1991), *Methods in Enzymology*, Vol. 194) lacking uracil, tryptophan, adenine and leucine to late logarithmic phase (approximately 6 OD₆₀₀/ml).

Agonists were prepared as 10 mM stocks in DMSO. EC₅₀ values (the concentration required to produce 50% maximal response) were estimated using dilutions of between 3- and 5-fold (BiomekFX, Beckman) into DMSO. Agonist solutions in DMSO (1% final assay volume) were transferred into black, clear bottom, microtitre plates from NUNC (96- or 384-well). Cells were suspended at a density of 0.2 OD₆₀₀/ml in SC media lacking histidine, uracil, tryptophan, adenine and leucine and supplemented with 10mM 3-aminotriazole, 0.1M sodium phosphate pH 7.0, and 20µM fluorescein di-β-D-glucopyranoside (FDGlu). This mixture (50ul per well for 384-well plates, 200ul per well for 96-well plates) was added to agonist in the assay plates (Multidrop 384, Labsystems). After incubation at 30°C for 24 hours, fluorescence resulting from degradation of FDGlu to fluorescein due to exoglucanase, an endogenous yeast enzyme produced during agonist-stimulated cell growth, was determined using a Spectrofluor microtitre plate reader (Tecan; excitation wavelength: 485nm; emission wavelength: 535nm). Fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter fit to generate a concentration effect value. Efficacy (E_{max}) was calculated from the equation

$$E_{\max} = \frac{\text{Max}_{[\text{compound X}]} - \text{Min}_{[\text{compound X}]}}{\text{Max}_{[\text{HU210}]} - \text{Min}_{[\text{HU210}]}} \times 100\%$$

where $\text{Max}_{[\text{compound X}]}$ and $\text{Min}_{[\text{compound X}]}$ are the fitted maximum and minimum respectively from the concentration effect curve for compound X, and $\text{Max}_{[\text{HU210}]}$ and $\text{Min}_{[\text{HU210}]}$ are the fitted maximum and minimum respectively from the concentration effect curve for (6aR,10aR)-3-(1,1'-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU210; available from Tocris). Equieffective molar ratio (EMR) values were calculated from the equation

$$\text{EMR} = \text{EC}_{50 [\text{compound X}]} / \text{EC}_{50 [\text{HU210}]}$$

Where $\text{EC}_{50 [\text{compound X}]}$ is the EC_{50} of compound X and $\text{EC}_{50 [\text{HU210}]}$ is the EC_{50} of HU210.

Compounds of the Examples tested according to this method had EC_{50} values >2000nM and/or efficacy values of <50% at the cloned human cannabinoid CB1 receptor.

Determination of cannabinoid CB2 Receptor Agonist Activity

The cannabinoid CB2 receptor agonist activity of the compounds of formula (I) was determined in accordance with the following experimental method.

Experimental Method

Yeast (*Saccharomyces cerevisiae*) cells expressing the human cannabinoid CB2 receptor were generated by integration of an expression cassette into the *ura3* chromosomal locus of yeast strain MMY23. This cassette consisted of DNA sequence encoding the human CB2 receptor flanked by the yeast GPD promoter to the 5' end of CB2 and a yeast transcriptional terminator sequence to the 3' end of CB2. MMY23 expresses a yeast/mammalian chimeric G-protein alpha subunit in which the C-terminal 5 amino acids of Gpa1 are replaced with the C-terminal 5 amino acids of human Gai3 (as described in Brown *et al.* (2000), *Yeast* 16:11-22). Cells were grown at 30°C in liquid Synthetic Complete (SC) yeast media (Guthrie and Fink (1991), Methods in Enzymology, Vol. 194) lacking uracil, tryptophan, adenine and leucine to late logarithmic phase (approximately 6 OD₆₀₀/ml).

Agonists were prepared as 10 mM stocks in DMSO. EC_{50} values (the concentration required to produce 50% maximal response) were estimated using dilutions of between 3- and 5-fold (BiomekFX, Beckman) into DMSO. Agonist solutions in DMSO (1% final assay volume) were transferred into black, clear bottom, microtitre plates from NUNC (96- or 384-well). Cells were suspended at a density of 0.2 OD₆₀₀/ml in SC media lacking histidine, uracil, tryptophan, adenine and leucine and supplemented with 10mM 3-aminotriazole, 0.1M sodium phosphate pH 7.0, and 20M fluorescein di-β-D-glucopyranoside (FDGlu). This mixture (50ul per well for 384-well plates, 200ul per well for 96-well plates) was added to agonist in the assay plates (Multidrop 384, Labsystems). After incubation at 30°C for 24 hours, fluorescence resulting from degradation of FDGlu to fluorescein due to exoglucanase, an endogenous yeast enzyme produced during agonist-stimulated cell growth, was determined using a Spectrofluor microtitre plate reader (Tecan; excitation wavelength: 485nm; emission wavelength: 535nm). Fluorescence was plotted against compound concentration and iteratively curve fitted using a four parameter fit to generate a concentration effect value. Efficacy (E_{max}) was calculated from the equation

$$E_{\text{max}} = \text{Max}_{[\text{compound X}]} - \text{Min}_{[\text{compound X}]} / \text{Max}_{[\text{HU210}]} - \text{Min}_{[\text{HU210}]} \times 100\%$$

where $\text{Max}_{[\text{compound X}]}$ and $\text{Min}_{[\text{compound X}]}$ are the fitted maximum and minimum respectively from the concentration effect curve for compound X, and $\text{Max}_{[\text{HU210}]}$ and $\text{Min}_{[\text{HU210}]}$ are the fitted

maximum and minimum respectively from the concentration effect curve for (6aR,10aR)-3-(1,1'-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol (HU210; available from Tocris). Equieffective molar ratio (EMR) values were calculated from the equation

$$5 \quad \text{EMR} = \text{EC}_{50} [\text{compound X}] / \text{EC}_{50} [\text{HU210}]$$

Where $\text{EC}_{50} [\text{compound X}]$ is the EC_{50} of compound X and $\text{EC}_{50} [\text{HU210}]$ is the EC_{50} of HU210.

Compounds of Examples 1 to 23 and 31 to 54 tested according to this method had EC_{50} values 20 to 300 nM and efficacy values of >50% at the cloned human cannabinoid CB2 receptor.

10 Compounds of Examples 24 to 30 tested according to this method had EC_{50} values 300 to 1000nM or efficacy values of > 50% at the cloned human cannabinoid CB2 receptor.

Compounds of Examples 55 to 73 tested according to this method had EC_{50} values > 1000nM or efficacy values of <50% at the cloned human cannabinoid CB2 receptor.


15 The following examples are illustrative, but not limiting of the embodiments of the present invention.

Reference Example 1: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide

20 (a). To a solution of benzyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate (0.50 g, ex Maybridge) in 1,4-dioxan (5 ml) was added 3-chloroaniline (0.85 ml) and the solution stirred at room temperature for 15 h. 1,4-Dioxan was removed under reduced pressure and ethyl acetate (15 ml) added. The solution was washed sequentially with 2N hydrochloric acid (10 ml) and water (3 x 10 ml), dried (MgSO_4), evaporated and triturated with hexane to afford benzyl 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (524 mg).

25 NMR (400MHz, DMSO- d_6) δ 5.35 (2H, s), 7.14 (1H, d), 7.35-7.45 (6H, m), 7.68 (1H, m), 7.98 (1H, s), 9.13 (1H, s), 10.95 (1H, s).

LC/MS, $t = 3.70$ min, $[\text{MH}^+]$ 408 and 410.




30

(b). To a solution of benzyl 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate (0.50 g) in ethanol (15 ml) was added a solution of potassium hydroxide (205 mg) in ethanol (10 ml) and the solution stirred at reflux for 15 h. Ethanol was removed under reduced pressure and water (15 ml) added. The solution was washed with ether and concentrated hydrochloric acid added to adjust the acidity to pH 1. The precipitated solid was filtered, washed with water and dried in vacuo at 50°C to afford 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (366 mg,).

35

NMR (400MHz, DMSO- d_6) δ 7.49 (1H, d), 7.71 (1H, t), 7.98 (1H, d), 8.33 (1H, s), 9.42 (1H, s), 11.15 (1H, s), 14.0 (1H, br s).

LC/MS, $t = 3.44$ min, $[MH^+]$ 318 and 320.



5


(c). To a solution of 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) in dimethylformamide (2 ml) was added successively N-ethylmorpholine (42 μ l), benzylamine (15 μ l), 1-hydroxybenzotriazole hydrate (23 mg) and 1-(3-dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (25 mg). The solution was stirred for 3 h and allowed to stand overnight. Dimethylformamide was removed under reduced pressure and ethyl acetate (5 ml) added. The solution was washed sequentially with 5% sodium bicarbonate solution (2.5 ml), water (2.5 ml), 5% citric acid solution (2.5 ml) and brine (2 x 2.5 ml), dried ($MgSO_4$) and evaporated to afford the title compound (45 mg).

10

NMR (400MHz, DMSO- d_6) δ 4.47 (2H, d), 7.10 (1H, d), 7.25 (1H, m), 7.36 (5H, m), 7.69 (1H, d), 7.98 (1H, s), 8.89 (1H, s), 9.12 (1H, t), 10.65 (1H, s).


15

LC/MS, $t = 3.23$ min, $[MH^+]$ 407 and 409.



Example 1: 1-[2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]piperidin-1-ylmethanone

20



In a manner similar to Reference Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and piperidine (13 μ l) afforded the title compound (38 mg).


25

NMR (400MHz, DMSO- d_6) δ 1.3-1.65 (6H, m), 3.28 (2H, s), 3.6 (2H, br s), 7.10 (1H, d), 7.37 (1H, t), 7.68 (1H, d), 7.96 (1H, s), 8.78 (1H, s), 10.55 (1H, s).

LC/MS, $t = 3.63$ min, $[MH^+]$ 385 and 387.


30

Example : 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid cyclopentylmethanamide




- 5 In a manner similar to Reference Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (100 mg) and cyclopentylmethanamine hydrochloride (63 mg, prepared as described in Kelley et al., J. Med. Chem., 40, 3207, (1997)) afforded the title compound (80 mg).
 NMR (400MHz, DMSO-d₆) δ 1.20-1.26 (2H, m), 1.48-1.67 (4H, m), 1.67-1.73 (2H, m), 2.06-2.10 (1H, quintuplet), 3.15-3.18 (2H, t), 7.09 (1H, dt), 7.37 (1H, q), 7.67 (1H, d), 7.96 (1H, d),
 10 8.60-8.63 (1H, t), 8.79 (1H, s), 10.60 (1H, s).
 LC/MS, t = 3.73 min, [MH⁺] 399.

Example 3: [2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]morpholin-4-yl-methanone



- 15 In a manner similar to Reference Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and morpholine (11.5 μ l) afforded the title compound (43 mg).
 NMR (400MHz, DMSO-d₆) δ 3.4-3.75 (8H, m), 7.10 (1H, d), 7.38 (1H, t), 7.68 (1H, d), 7.98 (1H, s), 8.80 (1H, s), 10.60 (1H, s).
 20 LC/MS, t = 3.29 min, [MH⁺] 387 and 389.

Example 4: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide




- 25 In a manner similar to Reference Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and cyclohexanemethylamine (15 mg) afforded the title compound (27 mg).
 30

NMR (400MHz, DMSO-d₆) δ 0.85-1.0 (2H, m), 1.1-1.3 (3H, m), 1.5 (1H, m), 1.55-1.8 (5H, m), 3.06 (2H, t), 7.09 (1H, d), 7.37 (1H, t), 7.68 (1H, d), 7.97 (1H, s), 8.58 (1H, t), 8.79 (1H, s), 10.6 (1H, s).

LC/MS, $t = 3.87$ min, $[MH^+]$ 413 and 415.

5

Example 5: 2-Phenylamino-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide



10


In a manner similar to Reference Example 1(c) 2-phenylamino-4-trifluoromethylpyrimidine-5-carboxylic acid (32 mg) and cyclohexanemethylamine (15 mg) afforded the title compound (33 mg).

NMR (400MHz, DMSO-d₆) δ 0.85-1.0 (2H, m), 1.05-1.3 (3H, m), 1.5 (1H, m), 1.55-1.8 (5H, m), 3.08 (2H, t), 7.06 (1H, d), 7.35 (2H, t), 7.76 (2H, d), 8.56 (1H, t), 8.74 (1H, s), 10.4 (1H, s).

15

LC/MS, $t = 3.66$ min, $[MH^+]$ 379.

Example 6: [2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-ylmethanone



20

In a manner similar to Reference Example 1(c) 2-(2,3-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (24 mg) and morpholine (10 μ l) afforded the title compound (17 mg).


NMR (400MHz, DMSO-d₆) δ 3.4-3.8 (8H, m), 7.40 (1H, t), 7.54 (1H, d), 7.60 (1H, d), 8.78 (1H, s), 10.15 (1H, s).

25

LC/MS, $t = 3.32$ min, $[MH^+]$ 421 and 423.

Example 7: [2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-ylmethanone

30




In a manner similar to Reference Example 1(c) 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (30 mg) and morpholine (10 μ l) afforded the title compound (31 mg).

- 5 NMR (400MHz, DMSO- d_6) δ 3.3-3.8 (8H, m), 7.52 (1H, d of d), 7.68 (1H, d), 7.76 (1H, d), 8.73 (1H, s), 10.05 (1H, s).
LC/MS, $t = 3.37$ min, $[MH^+]$ 421 and 423.

Example 8: [2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone

10




In a manner similar to Reference Example 1(c) 2-(3,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (30 mg) and morpholine (10 μ l) afforded the title compound (36 mg).

15

- NMR (400MHz, DMSO- d_6) δ 3.35-3.8 (8H, m), 7.67 (1H, d), 7.76 (1H, d of d), 8.22 (1H, s), 8.90 (1H, s), 10.80 (1H, s).
LC/MS, $t = 3.45$ min, $[MH^+]$ 421 and 423.

Example 9: [2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone

20




In a manner similar to Reference Example 1(c) 2-(2,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and morpholine (14.5 μ l) afforded the title compound (27 mg).

25

- NMR (400MHz, DMSO- d_6) δ 3.4-3.75 (8H, m), 7.32 (1H, d of d), 7.66 (1H, d), 7.78 (1H, d), 8.71 (1H, s), 10.05 (1H, s).
LC/MS, $t = 3.31$ min, $[MH^+]$ 421 and 423.

30

Example 10: [2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone

5


In a manner similar to Reference Example 1(c) 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and morpholine (12 μ l) afforded the title compound (31 mg).

NMR (400MHz, DMSO- d_6) δ 3.4-3.8 (8H, m), 6.85 (1H, t of d), 7.37 (1H, q), 7.52 (1H, d), 7.77 (1H, d of t), 8.80 (1H, s), 10.65 (1H, s).

LC/MS, $t = 3.06$ min, $[MH^+]$ 371.

Example 11: [2-(3-Bromophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone

15




In a manner similar to Reference Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and morpholine (10 μ l) afforded the title compound (31 mg).

NMR (400MHz, DMSO- d_6) δ 3.4-3.8 (8H, m), 7.22 (1H, d), 7.30 (1H, t), 7.71 (1H, d), 8.11 (1H, s), 8.81 (1H, s), 10.60 (1H, s).

LC/MS, $t = 3.25$ min, $[MH^+]$ 431 and 433.

Example 12: [2-(3-Bromophenylamino)-4-trifluoromethylpyrimidin-5-yl]-piperidin-4-ylmethanone


25



In a manner similar to Reference Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and piperidine (12 μ l) afforded the title compound (31 mg).

NMR (400MHz, DMSO-d₆) δ 1.3-1.7 (6H, m), 3.26 (2H, s), 3.60 (2H, br s), 7.21 (1H, d), 7.30 (1H, t), 7.70 (1H, d), 8.11 (1H, s), 8.78 (1H, s), 10.55 (1H, s).
LC/MS, $t = 3.57$ min, $[MH^+]$ 429 and 431.

5 **Example 13: [2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidin-5-yl]-morpholin-4-yl-methanone**




10 In a manner similar to Reference Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and morpholine (14.5 μ l) afforded the title compound (42 mg).

NMR (400MHz, DMSO-d₆) δ 3.4-3.75 (8H, m), 7.35 (1H, s), 7.89 (2H, s), 8.87 (1H, s), 10.80 (1H, s).

15 LC/MS, $t = 3.52$ min, $[MH^+]$ 421 and 423.

Example 14: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidin-5-carboxylic acid N-cyclopentylamide



20


In a manner similar to Reference Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and cyclopentylamine (13 μ l) afforded the title compound (34 mg).

25 NMR (400MHz, DMSO-d₆) δ 1.5 (4H, m), 1.65 (2H, m), 1.85 (2H, m), 4.15 (1H, m), 7.09 (1H, d), 7.36 (1H, t), 7.67 (1H, d), 7.97 (1H, s), 8.55 (1H, d), 8.79 (1H, s), 10.60 (1H, s).

LC/MS CF103478-1, $t = 3.55$ min, $[MH^+]$ 385 and 387.

Example 15: 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide

30




In a manner similar to Reference Example 1(c) 2-(2,3-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and cyclohexanemethylamine (16 μ l) afforded the title compound (30 mg).

- 5 NMR (400MHz, DMSO-d₆) δ 0.85-1.0 (2H, m), 1.1-1.3 (3H, m), 1.45 (1H, m), 1.55-1.8 (5H, m), 3.05 (2H, t), 7.40 (1H, t), 7.55 (2H, d), 8.53 (1H, t), 8.65 (1H, s), 10.15 (1H, s).
LC/MS, $t = 3.84$ min, $[MH^+]$ 447 and 449.

Example 16: 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide

10




In a manner similar to Reference Example 1(c) 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and cyclohexanemethylamine (16 μ l) afforded the title compound (14 mg).

- 15 NMR (400MHz, DMSO-d₆) δ 0.85-1.0 (2H, m), 1.1-1.3 (3H, m), 1.45 (1H, m), 1.55-1.75 (5H, m), 3.05 (2H, t), 7.46 (1H, d), 7.57 (1H, d), 7.72 (1H, s), 8.53 (1H, t), 8.64 (1H, s), 10.00 (1H, s).
LC/MS, $t = 3.90$ min, $[MH^+]$ 447 and 449.

Example 17: 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide

20




In a manner similar to Reference Example 1(c) 2-(3,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and cyclohexanemethylamine (16 μ l) afforded the title compound (31 mg).

- 25 NMR (400MHz, DMSO-d₆) δ 0.8-1.0 (2H, m), 1.1-1.3 (3H, m), 1.5 (1H, m), 1.55-1.8 (5H, m), 3.06 (2H, t), 7.62 (1H, d), 7.69 (1H, d), 8.18 (1H, s), 8.59 (1H, t), 8.82 (1H, s), 10.70 (1H, s).
LC/MS, $t = 4.01$ min, $[MH^+]$ 447 and 449.


30

Example 18: 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide




- 5 In a manner similar to Reference Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and cyclohexanemethylamine (16 μ l) afforded the title compound (30 mg).
 NMR (400MHz, DMSO-d₆) δ 0.85-1.0 (2H, m), 1.1-1.3 (3H, m), 1.5 (1H, m), 1.55-1.8 (5H, m), 3.07 (2H, t), 7.26 (1H, s), 7.89 (2H, s), 8.58 (1H, t), 8.86 (1H, s), 10.80 (1H, s).
 10 LC/MS, t = 4.08 min, [MH⁺] 447 and 449.

Example 19: 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide



- 15 In a manner similar to Reference Example 1(c) 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and cyclohexanemethylamine (18 μ l) afforded the title compound (38 mg).
 NMR (400MHz, DMSO-d₆) δ 0.85-1.0 (2H, m), 1.1-1.3 (3H, m), 1.5 (1H, m), 1.55-1.8 (5H, m), 3.09 (2H, t), 6.87 (1H, t of d), 7.39 (1H, q), 7.53 (1H, d), 7.78 (1H, d of t), 8.59 (1H, t), 8.80 (1H, s), 10.60 (1H, s).
 20 LC/MS, t = 3.68 min, [MH⁺] 397.

Example 20: 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide




- 25 In a manner similar to Reference Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and cyclohexanemethylamine (15 μ l) afforded the title compound (36 mg).
 30

NMR (400MHz, DMSO-d₆) δ 0.85-1.0 (2H, m), 1.1-1.3 (3H, m), 1.5 (1H, m), 1.55-1.8 (5H, m), 3.08 (2H, t), 7.23 (1H, d), 7.31 (1H, t), 7.71 (1H, d), 8.10 (1H, s), 8.57 (1H, t), 8.80 (1H, s), 10.60 (1H, s).

LC/MS, $t = 3.85$ min, $[MH^+]$ 457 and 459.

5

Example 21: 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclohexylmethyl)amide




- 10 In a manner similar to Reference Example 1(c) 2-(2,6-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (33 mg) and cyclohexanemethylamine (15 μ l) afforded the title compound (9 mg).

NMR (400MHz, DMSO-d₆) δ 0.85-1.0 (2H, m), 1.05-1.25 (3H, m), 1.46 (1H, m), 1.55-1.8 (5H, m), 3.04 (2H, t), 7.39 (1H, t), 7.59 (2H, d), 8.56 (2H, m), 10.10 (1H, s).

- 15 LC/MS, $t = 3.84$ min, $[MH^+]$ 447 and 449.

Example 22: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydro-pyran-4-ylmethyl)amide




20

In a manner similar to Reference Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (30 mg) and 4-aminomethyltetrahydropyran (13 mg) afforded the title compound (25 mg).

- 25 NMR (400MHz, DMSO-d₆) δ 1.15-1.3 (2H, m), 1.62 (2H, d), 1.74 (1H, m), 3.13 (2H, t), 3.27 (2H, t), 3.86 (2H, d), 7.10 (1H, d), 7.37 (1H, t), 7.66 (1H, d), 7.97 (1H, s), 8.63 (1H, t), 8.82 (1H, s), 10.60 (1H, s).

LC/MS, $t = 3.22$ min, $[MH^+]$ 415 and 417.

- 30 **Example 23: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidin-5-carboxylic acid N-(cyclobutyl)amide**



In a manner similar to Reference Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (35 mg) and cyclobutylamine (10 μ l) afforded the title compound (28 mg).

NMR (400MHz, DMSO- d_6) δ 1.6-1.75 (2H, m), 1.9-2.05 (2H, m), 2.2-2.3 (2H, m), 4.32 (1H, m), 7.10 (1H, d), 7.37 (1H, t), 7.67 (1H, d), 7.96 (1H, s), 8.82 (2H, s), 10.60 (1H, s).
LC/MS, $t = 3.45$ min, $[MH^+]$ 371 and 373.


10 Examples 24 to 30

In the following table giving examples 24 to 30, columns 1 and 2 give precursors that were reacted in a manner similar to that in Reference example 1(a). In a manner similar to that in Reference example 1(b), the carboxylic acid of the resultant ester was prepared. Finally, in a manner similar to that of Reference example 1(c), the resultant acid product was reacted with the precursor of column 3 to provide the final product of column 4.

Ex	1	2	3	4 - Product
24	Methyl 2-chloro-4-(Trifluoromethyl)pyrimidine-5-carboxylate	Aniline	Piperidine	(2-Phenylamino-4-trifluoromethyl-pyrimidin-5-yl)-piperidin-1-yl-methanone
25	Methyl 2-chloro-4-(Trifluoromethyl)pyrimidine-5-carboxylate	Aniline	Morpholine	Morpholin-4-yl(2-phenylamino-4-trifluoromethyl-pyrimidin-5-yl)-methanone
26	Methyl 2-chloro-4-(Trifluoromethyl)pyrimidine-carboxylate	3-Chloroaniline	Aminoacetonitrile	2-(3-Chloro-phenylamino)- 4-trifluoromethyl-pyrimidine-5-carboxylic acid cyanomethyl-amide
27	Methyl 2-chloro-4-(Trifluoromethyl)pyrimidine-5-carboxylate	3-Chloroaniline	3,3-Dimethylbutylamine	2-(3-Chloro-phenylamino)- 4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(3,3-dimethyl-butyl)-amide

28	Methyl 2-chloro-4-(Trifluoromethyl)pyrimidine-5-carboxylate	3-Chloroaniline	Neopentylamine	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid N-(2,2-dimethyl-propyl)-amide
29	Methyl 2-chloro-4-(trifluoromethyl)-pyrimidine-5-carboxylate	3-Fluoroaniline	Cyclobutylamine	2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclobutylamide
30	Methyl 2-chloro-4-(trifluoromethyl)-pyrimidine-5-carboxylate	3,4-Dichloroaniline	Cyclobutylamine	2-(3,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclobutylamide

Example 31: 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide



5


In a manner similar to Reference Example 1(c) 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-aminomethyltetrahydropyran (16 mg) afforded the title compound (38 mg).

10 NMR (400MHz, DMSO-d₆) δ 1.15-1.3 (2H, m), 1.63 (2H, d), 1.75 (1H, m), 3.15 (2H, t), 3.29 (2H, t), 3.86 (2H, d), 6.88 (1H, td), 7.38 (1H, q), 7.51 (1H, d), 7.76 (1H, dt), 8.64 (1H, t), 8.82 (1H, s), 10.60 (1H, s).

LC/MS, t = 3.08 min, [MH⁺] 399.

Example 32: 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide

15




20 In a manner similar to Reference Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and 4-aminomethyltetrahydropyran (13.5 mg) afforded the title compound (36 mg).

NMR (400MHz, DMSO-d₆) δ 1.15-1.3 (2H, m), 1.62 (2H, d), 1.74 (1H, m), 3.13 (2H, t), 3.27 (2H, t), 3.86 (2H, d), 7.23 (1H, d), 7.31 (1H, t), 7.71 (1H, d), 8.11 (1H, s), 8.63 (1H, t), 8.82 (1H, s), 10.60 (1H, s).

LC/MS, $t = 3.26$ min, $[MH^+]$ 459 and 461.

5

Example 33: 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide




10 In a manner similar to Reference Example 1(c) 2-(2,3-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (30 mg) and 4-aminomethyltetrahydropyran (12 mg) afforded the title compound (25 mg).

NMR (400MHz, DMSO-d₆) δ 1.1-1.25 (2H, m), 1.60 (2H, d), 1.72 (1H, m), 3.11 (2H, t), 3.26 (2H, t), 3.85 (2H, d), 7.40 (1H, t), 7.55 (2H, d), 8.60 (1H, t), 8.66 (1H, s), 10.10 (1H, s).

15 LC/MS, $t = 3.29$ min, $[MH^+]$ 449 and 451.

Example 34: 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide



20


In a manner similar to Reference Example 1(c) 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (30 mg) and 4-aminomethyltetrahydropyran (12 mg) afforded the title compound (34 mg).

25 NMR (400MHz, DMSO-d₆) δ 1.1-1.25 (2H, m), 1.59 (2H, d), 1.72 (1H, m), 3.11 (2H, t), 3.26 (2H, t), 3.85 (2H, d), 7.47 (1H, dd), 7.57 (1H, d), 7.72 (1H, s), 8.60 (1H, t), 8.65 (1H, s), 10.05 (1H, s).

LC/MS, $t = 3.33$ min, $[MH^+]$ 449 and 451.

Example 35: 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide

30




In a manner similar to Reference Example 1(c) 2-(2,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (50 mg) and 4-aminomethyltetrahydropyran (25 mg) afforded the title compound (63 mg).

- 5 NMR (400MHz, DMSO-d₆) δ 1.15-1.3 (2H, m), 1.60 (2H, d), 1.72 (1H, m), 3.12 (2H, t), 3.27 (2H, t), 3.85 (2H, d), 7.35 (1H, dd), 7.59 (1H, d), 7.73 (1H, s), 8.62 (1H, t), 8.70 (1H, s), 10.05 (1H, s).

LC/MS, $t = 3.30$ min, $[MH^+]$ 449 and 451.


10 **Example 36: 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide**



In a manner similar to Reference Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (50 mg) and 4-aminomethyltetrahydropyran (25 mg) afforded the title compound (68 mg).

- 15 NMR (400MHz, DMSO-d₆) δ 1.15-1.35 (2H, m), 1.62 (2H, d), 1.72 (1H, m), 3.14 (2H, t), 3.28 (2H, t), 3.86 (2H, d), 7.25 (1H, s), 7.88 (2H, s), 8.66 (1H, t), 8.88 (1H, s), 10.75 (1H, s).

20 **Example 37: 2-(3-methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(tetrahydropyran-4-ylmethyl)amide**




In a manner similar to Reference Example 1(c) 2-(3-methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (32 mg) and 4-aminomethyltetrahydropyran (14.5 mg) afforded the title compound (29 mg).

- 25 NMR (400MHz, DMSO-d₆) δ 1.1-1.25 (2H, m), 1.61 (2H, d), 1.74 (1H, m), 3.13 (2H, t), 3.27 (2H, t), 3.74 (3H, s), 3.86 (2H, d), 6.63 (1H, d), 7.25 (2H, m), 7.53 (1H, s), 8.62 (1H, t), 8.76 (1H, s), 10.35 (1H, s).

LC/MS, $t = 2.97$ min, $[MH^+]$ 411.

Example 38: 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide

5




In a manner similar to Reference Example 1(c) 2-(3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (30 mg) and cyclopentylmethylamine hydrochloride (17 mg, prepared as described in Kelley et al., J. Med. Chem., **40**, 3207, (1997)) afforded the title compound (17 mg).

10 NMR (400MHz, DMSO- d_6) δ 1.20-1.30 (2H, m), 1.45-1.68 (4H, m), 1.68-1.77 (2H, m), 2.1 (1H, quintuplet), 3.19 (2H, t), 6.89 (1H, dt), 7.40 (1H, q), 7.54 (1H, d), 7.78 (1H, d), 8.64 (1H, t), 8.80 (1H, s), 10.70 (1H, s).

LC/MS, $t = 3.53$ min, $[MH^+]$ 383.

15 **Example 39: 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide**




In a manner similar to Reference Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (36.5 mg) and cyclopentylmethylamine hydrochloride (17 mg) afforded the title compound (28 mg).

20 NMR (400MHz, DMSO- d_6) δ 1.39-1.52 (2H, m), 1.69-1.90 (4H, m), 1.90- 2.02 (2H, m), 2.34 (1H, quintuplet), 3.4 (2H, t), 7.48 (1H, d), 7.57 (1H, t), 7.95 (1H, d), 8.37 (1H, s), 8.86 (1H, t), 9.02 (1H, s), 10.80 (1H, s).

25 LC/MS, $t = 3.33$ min, $[MH^+]$ 443 and 445.


Example 40: 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide



In a manner similar to Reference Example 1(c) 2-(2,3-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (32 mg) and cyclopentylmethylamine hydrochloride (15 mg) afforded the title compound (30 mg).

- 5 NMR (400MHz, DMSO-d₆) δ 1.15-1.30 (2H, m), 1.44-1.78 (6H, m), 2.10 (1H, quintuplet), 3.16 (2H, t), 7.41 (2H, t), 7.54 (1H, m), 8.58 (1H, br t), 8.78 (1H, s), 10.10 (1H, s).
LC/MS, t = 3.71 min, [MH⁺] 433 and 435.


Example 41: 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide



In a manner similar to Reference Example 1(c) 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (32 mg) and cyclopentylmethylamine hydrochloride (15 mg) afforded the title compound (27 mg).

- 15 NMR (400MHz, DMSO-d₆) δ 1.2-1.3 (2H, m), 1.4-1.79 (6H, m), 2.10 (1H, quintuplet), 3.17 (2H, t), 7.50 (1H, d), 7.60 (1H, d), 7.75 (1H, d), 8.68 (1H, t), 8.78 (1H, s), 10.10 (1H, s).
LC/MS, t = 3.76 min, [MH⁺] 433 and 435.

Example 42: 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide




In a manner similar to Reference Example 1(c) 2-(2,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (32 mg) and cyclopentylmethylamine hydrochloride (15 mg) afforded the title compound (23 mg).

- 25 NMR (400MHz, DMSO-d₆) δ 1.15-1.30 (2H, m), 1.45-1.79 (6H, m), 2.08 (1H, quintuplet), 3.18 (2H, t), 7.38 (1H, d), 7.62 (1H, d), 7.75 (1H, s), 8.61 (1H, br t), 8.71 (1H, s), 10.05 (1H, s).

LC/MS, $t = 3.76$ min, $[MH^+]$ 433 and 435.

**Example 43: 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid
N-(cyclopentylmethyl)amide**

5




In a manner similar to Reference Example 1(c) 2-(2,6-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (32 mg) and cyclopentylmethylamine hydrochloride (15 mg) afforded the title compound (25 mg).

- 10 NMR (400MHz, DMSO- d_6) δ 1.15-1.30 (2H, m), 1.45-1.78 (6H, m), 2.08 (1H, quintuplet), 3.15 (2H, t), 7.4 (1H, t), 7.6-7.68 (2H, m), 8.5-8.7 (2H, m), 10.20 (1H, s).
LC/MS, $t = 3.49$ min, $[MH^+]$ 433 and 435.

**Example 44: 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid
N-(cyclopentylmethyl)amide**

15




In a manner similar to Reference Example 1(c) 2-(3,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (32 mg) and cyclopentylmethylamine hydrochloride (15 mg) afforded the title compound (29 mg).

- 20 NMR (400MHz, DMSO- d_6) δ 1.12-1.3 (2H, m), 1.44-1.8 (6H, m), 2.1 (1H, quintuplet), 3.17 (2H, t), 7.62 (1H, br d), 7.72 (1H, d), 8.18 (1H, d), 8.60-8.69 (1H, br t), 8.83 (1H, s), 10.80 (1H, s).
LC/MS, $t = 3.87$ min, $[MH^+]$ 433 and 435.

**Example 45: 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid
N-(cyclopentylmethyl)amide**

25




In a manner similar to Reference Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (32 mg) and cyclopentylmethylamine hydrochloride (15 mg) afforded the title compound (27 mg).

NMR (400MHz, DMSO-d₆) 1.14-1.34 (2H, m), 1.45-1.8 (6H, m), 2.10 (1H, quintuplet), 3.20 (2H, t), 7.28 (1H, s), 7.91 (2H, s), 8.6-8.7 (1H, br t), 8.9 (1H, s), 10.75 (1H, s).

LC/MS, t = 3.94 min, [MH⁺] 433 and 435.

Example 46: 2-(3-Methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclopentylmethyl)amide




In a manner similar to Reference Example 1(c) 2-(3-methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (32 mg) and cyclopentylmethylamine hydrochloride (17 mg) afforded the title compound (21 mg).

NMR (400MHz, DMSO-d₆) 1.25-1.38 (2H, m), 1.50-1.85 (6H, m), 2.15 (1H, quintuplet), 3.25 (2H, t), 3.85 (3H, s), 6.70 (1H, br d), 7.26-7.37 (2H, m), 7.60 (1H, m), 8.68 (1H, t), 8.80 (1H, s), 10.50 (1H, s).

LC/MS, t = 3.46 min, [MH⁺] 395.

Example 47: 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide




In a manner similar to Reference Example 1(c) 2-(3-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (35 mg) and cyclobutylamine (10 μl) afforded the title compound (30 mg).

NMR (400MHz, DMSO-d₆) δ 1.70 (2H, m), 1.97 (2H, m), 2.22 (2H, m), 4.32 (1H, m), 7.22-7.33 (2H, m), 7.70 (1H, d), 8.10 (1H, s), 8.81-8.83 (2H, m), 10.60 (1H, s).

LC/MS, t = 3.47 min, [MH⁺] 415 and 417.

Example 48: 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid -cyclobutylamide




In a manner similar to Reference Example 1(c) 2-(2,3-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (25 mg) and cyclobutylamine (10 μ l) afforded the title compound (20 mg).

- 5 NMR (400MHz, DMSO-d₆) δ 1.70 (2H, m), 1.97 (2H, m), 2.22 (2H, m), 4.32 (1H, m), 7.38-7.56 (3H, m), 8.65 (1H, s), 8.80 (1H, d), 10.10 (1H, s).
LC/MS, t = 3.48 min, [MH⁺] 405 and 407.

Example 49: 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide

10




In a manner similar to Reference Example 1(c) 2-(2,4-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (30 mg) and cyclobutylamine (10 μ l) afforded the title compound (26 mg).

15

- NMR (400MHz, DMSO-d₆) δ 1.70 (2H, m), 1.97 (2H, m), 2.22 (2H, m), 4.32 (1H, m), 7.46-7.72 (3H, m), 8.64 (1H, s), 8.80 (1H, d), 10.00 (1H, s).
LC/MS, t = 3.54 min, [MH⁺] 405 and 407.

20

Example 50: 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide



In a manner similar to Reference Example 1(c) 2-(2,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (50 mg) and cyclobutylamine (19 μ l) afforded the title compound (56 mg).


25

- NMR (400MHz, DMSO-d₆) δ 1.70 (2H, m), 1.97 (2H, m), 2.22 (2H, m), 4.30 (1H, m), 7.33-7.73 (3H, m), 8.70 (1H, s), 8.80 (1H, d), 10.00 (1H, s).

LC/MS, $t = 3.52$ min, $[MH^+]$ 405 and 407.

Example 51: 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide

5




In a manner similar to Reference Example 1(c) 2-(2,6-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (30 mg) and cyclobutylamine (10 μ l) afforded the title compound (34 mg).

10 NMR (400MHz, DMSO- d_6) δ 1.70 (2H, m), 1.97 (2H, m), 2.22 (2H, m), 4.30 (1H, m), 7.36-7.60 (3H, m), 8.59 (1H, s), 8.80 (1H, d), 10.15 (1H, s).

LC/MS, $t = 3.24$ min, $[MH^+]$ 405 and 407.

Example 52: 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide

15



In a manner similar to Reference Example 1(c) 2-(3,5-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (50 mg) and cyclobutylamine (19 μ l) afforded the title compound (56 mg).


20

NMR (400MHz, DMSO- d_6) δ 1.70 (2H, m), 1.97 (2H, m), 2.22 (2H, m), 4.32 (1H, m), 7.25-7.87 (3H, m), 8.85 (1H, d), 8.88 (1H, s), 10.80 (1H, s).

LC/MS, $t = 3.73$ min, $[MH^+]$ 405 and 407.

Example 53: 2-(3-methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-cyclobutylamide

25



In a manner similar to Reference Example 1(c) 2-(3-methoxyphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (32 mg) and cyclobutylamine (10.5 μ l) afforded the title compound (27 mg).


NMR (400MHz, DMSO-d₆) δ 1.70 (2H, m), 1.97 (2H, m), 2.22 (2H, m), 3.75 (3H, s), 4.32 (1H, m), 7.53-7.87 (4H, m), 8.76 (1H, s), 8.81 (1H, d), 10.40 (1H, s).

LC/MS, t = 3.20 min, [MH⁺] 367.

Example 54: 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid N-(cyclobutylmethyl)amide

(a) A solution of borane-tetrahydrofuran complex (1M in tetrahydrofuran, 120ml) was added over 10min to a solution of cyclobutane carbonitrile (8.1g) [Lancaster] in dry tetrahydrofuran (20ml) under nitrogen at room temperature. The solution was refluxed overnight then cooled to 20°. Methanol (150ml) was added dropwise over 15mins keeping the temperature below 25°, then the mixture was cooled to 0° and dry hydrogen chloride was bubbled through for 30min. The resulting mixture was refluxed for 90min, evaporated and the residue re-evaporated twice from methanol. Ether (150ml) was added and the resulting solid was filtered off. It was taken up in hot isopropanol (50ml), filtered, and hot acetonitrile (30ml) added. The mixture was cooled and the solid filtered off to give the C-cyclobutylmethylamine hydrochloride (5.7g)


NMR (400 MHz, DMSO-d₆) F6382 1.8 (4H, m), 2.0 (2H, m), 2.54 (1H, m), 2.80 (2H, d), 8.0 (3H, br s).




(b) In a manner similar to Reference Example 1(c) 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (32 mg) and C-cyclobutylmethylamine hydrochloride (13 mg) afforded the title compound (28 mg).

NMR (400MHz, DMSO-d₆) δ 1.70 (2H, m), 1.82 (2H, m), 2.00 (2H, m), 2.50 (1H, m), 3.26 (2H, m), 7.08-7.95 (4H, m), 8.55 (1H, t), 8.77 (1H, s), 10.60 (1H, s).

LC/MS, t = 3.56 min, [MH⁺] 385.



Examples 55 to 72 were prepared in a corresponding fashion to the above compounds.



Ex no	name	R ¹	m	R ³	Z
55	2-(2,6-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide	H	1	tetrahydropyran-4-yl	2,6di-Cl
56	2-(3,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (tetrahydro-pyran-4-ylmethyl)-amide	H	1	tetrahydropyran-4-yl	3,4di-Cl
57	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cycloheptylamide	H	0	cycloheptyl	3Cl
58	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid [(S)-1-(tetrahydrofuran-2-yl)methyl]-amide	H	1	(S)-1-(tetrahydrofuran-2-yl)	3Cl
59	2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid [(S)-1-(tetrahydrofuran-2-yl)methyl]-amide	H	1	(S)-1-(tetrahydrofuran-2-yl)	3 F
60	2-(3-Bromo-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid [(S)-1-(tetrahydrofuran-2-yl)methyl]-amide	H	1	(S)-1-(tetrahydrofuran-2-yl)	3 Br
61	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (1-methanesulfonyl-piperidin-4-ylmethyl)-amide	H	1	1-methanesulfonyl-piperidin-4-yl	3 Cl
62	2-(2,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclohexylmethyl-amide	H	1	cyclohexyl	2,5 diCl
63	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (1-ethyl-propyl)-amide	H	0	1-ethyl-propyl	3Cl
64	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid <i>tert</i> -butylamide	H	0	t-Bu	3 Cl

65	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (tetrahydro-pyran-4-yl)-amide	H	0	tetrahydropyran-4-yl	3 Cl
66	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid cyclohexylamide	H	0	cyclohexyl	3Cl
67	1-[2-(3,5-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidin-5-yl]-1-piperidin-1-yl-methanone	piperidin-1-yl			3,5 diCl
68	1-[2-(3,4-Dichloro-phenylamino)-4-trifluoromethyl-pyrimidin-5-yl]-1-morpholin-4-yl-methanone	morphin-4-yl			3,4 diCl
69	2-Phenylamino-4-trifluoromethyl-pyrimidine-5-carboxylic acid (2,2-dimethyl-propyl)-amide	H	1	t-Bu	H
70	2-Phenylamino-4-trifluoromethyl-pyrimidine-5-carboxylic acid (3,3-dimethyl-butyl)-amide	H	0	3,3 dimethylbutyl	H
71	2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid (piperidin-4-ylmethyl)-amide	H	1	piperidin-4-yl	3Cl
72	1-[2-(3-Chloro-phenylamino)-4-trifluoromethyl-pyrimidin-5-yl]-1-piperazin-1-yl-methanone	piperazin-1-yl			3Cl
73	2-(3-Fluoro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid [(R)-1-(tetrahydro-furan-2-yl)methyl]-amide	(R)-1-(tetrahydro-furan-2-yl)			3-F

Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.

Example 74: Inhalant Formulation

A compound of formula (I) or a pharmaceutically acceptable derivative thereof, (1 mg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.

Example 75: Tablet Formulation

	<u>Tablets/Ingredients</u>	<u>Per Tablet</u>
15	1. Active ingredient (Compound of formula (I) or pharmaceutically acceptable derivative)	40 mg
	2. Corn Starch	20 mg
	3. Alginic acid	20 mg

- | | | |
|----|-----------------|--------|
| 4. | Sodium Alginate | 20 mg |
| 5. | Mg stearate | 1.3 mg |

5 Procedure for tablet formulation:


Ingredients 1, 2, 3 and 4 are blended in a suitable mixer/blender. Sufficient water is added portion-wise to the blend with careful mixing after each addition until the mass is of a consistency to permit its conversion to wet granules. The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen. The wet granules are then dried in an oven at 140°F (60°C) until dry. The dry granules are lubricated with ingredient No. 5, and the lubricated granules are compressed on a suitable tablet press.

10 Example 76: Parenteral Formulation

A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount of a compound of formula (I) in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then rendered sterile by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Claims

1. A compound of formula (I):



wherein:

Y is phenyl, optionally substituted with one, two or three substituents;

R¹ is selected from: hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl;


R² is (CH₂)_mR³ where m is 0 or 1;

or R¹ and R² together with N to which they are attached form an optionally substituted 5- or 6- membered non-aromatic heterocyclyl ring;

R³ is an optionally substituted 4- to 8- membered non-aromatic heterocyclyl group, an optionally substituted C₃₋₈ cycloalkyl group, an optionally substituted straight or branched C₁₋₁₀ alkyl or R⁵;

R⁴ is selected from: hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or halosubstituted C₁₋₆ alkyl, COCH₃, or SO₂Me;

R⁵ is



wherein p is 0, 1 or 2;

R⁶ is methyl, chloro or CH_xF_n wherein n is 1, 2, or 3, x is 0, 1 or 2 and n and x add up to

3;

R⁷ is OH, C₁₋₆alkoxy, NR^{8a}R^{8b}, NHCOR⁹, NHSO₂R⁹, SO_qR⁹;

R^{8a} is H or C₁₋₆alkyl;

R^{8b} is H or C₁₋₆alkyl;

R⁹ is C₁₋₆alkyl;

q is 0, 1 or 2;

and pharmaceutically acceptable derivatives thereof.

and a pharmaceutically acceptable derivative thereof.

2. A compound as claimed in claim 1 selected from any one of examples 1 to 73 or a pharmaceutically acceptable derivative thereof.

3. A pharmaceutical composition comprising a compound as claimed in claim 1 or 2 or a pharmaceutically acceptable derivative thereof and a pharmaceutical carrier or diluent thereof.

4. A method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in claim 1 or 2 or a pharmaceutically acceptable derivative thereof.

5

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.